MX2021002657A - Nuevos conjugados de montelukast y péptidos. - Google Patents
Nuevos conjugados de montelukast y péptidos.Info
- Publication number
- MX2021002657A MX2021002657A MX2021002657A MX2021002657A MX2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A MX 2021002657 A MX2021002657 A MX 2021002657A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- peptide
- containing compound
- montelukast
- sup
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105703 | 2018-09-14 | ||
| CN2018119072 | 2018-12-04 | ||
| PCT/CN2019/105832 WO2020052677A1 (en) | 2018-09-14 | 2019-09-14 | New conjugates of montelukast and peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002657A true MX2021002657A (es) | 2021-07-21 |
Family
ID=69777394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002657A MX2021002657A (es) | 2018-09-14 | 2019-09-14 | Nuevos conjugados de montelukast y péptidos. |
Country Status (27)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3068818A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Mucocare Pharmaceutical Co., Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
| EP4028409A4 (en) * | 2019-09-14 | 2023-10-11 | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | NEW PEPTIDES |
| US20240218016A1 (en) * | 2019-12-02 | 2024-07-04 | Shenzhen Institutes Of Advanced Technology | Peptides and their use in the treatment of inflammation |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| WO2021207606A1 (en) * | 2020-04-10 | 2021-10-14 | University Of Georgia Research Foundation, Inc. | Methods for treatment of coronavirus infections |
| KR102596264B1 (ko) * | 2020-11-30 | 2023-11-01 | 주식회사 바이오빛 | 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물 |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| WO2022193185A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New conjugates |
| WO2023225107A1 (en) * | 2022-05-17 | 2023-11-23 | Emory University | Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions |
| JP2026506026A (ja) * | 2023-02-13 | 2026-02-20 | エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド | 新規多機能オリゴペプチド |
| AU2024312518A1 (en) * | 2023-06-22 | 2026-01-22 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New multi-functional oligopeptides |
| CN122028898A (zh) * | 2023-10-23 | 2026-05-12 | 艾缇亚(上海)制药有限公司 | 新型短链肽及其衍生物 |
| WO2025110754A1 (ko) * | 2023-11-22 | 2025-05-30 | 한도숙 | 상처 치료 또는 피부 주름형성 억제용 조성물 |
| WO2025195444A1 (en) | 2024-03-20 | 2025-09-25 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | New use of peptides derived from vasoactive intestinal peptide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| WO2003020200A2 (en) | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| EP2316468A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2004005309A2 (en) | 2002-07-08 | 2004-01-15 | Pliva - Istrazivacki Institut D.O.O. | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| US20050107612A1 (en) | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
| KR101224235B1 (ko) * | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 il9 항체 및 그의 용도 |
| US7582297B2 (en) * | 2003-04-11 | 2009-09-01 | Medimmune, Llc | Methods of treating respiratory conditions |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| JP2007510621A (ja) | 2003-07-29 | 2007-04-26 | シグニチャー アールアンドディー ホールディングス,エルエルシー. | アミノ酸プロドラッグ |
| DE602005018672D1 (de) * | 2004-10-27 | 2010-02-11 | Glaxosmithkline Zagreb | Konjugate mit entzündungshemmender aktivität |
| TW200740441A (en) * | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| CA2773737C (en) * | 2009-09-09 | 2021-11-16 | Pharmain Corporation | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same |
| CN102068432A (zh) | 2011-01-11 | 2011-05-25 | 李仲昆 | 一种由他定类和白三烯拮抗剂组成的外用复方组合物 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| HK1207562A1 (en) | 2012-01-18 | 2016-02-05 | 苏州泰飞尔医药有限公司 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| EP2968309A4 (en) * | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| US20160060328A1 (en) * | 2013-10-25 | 2016-03-03 | Lpath, Inc. | Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| BR112018000953A2 (pt) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| CN110945016A (zh) | 2017-05-24 | 2020-03-31 | 特拉斯福特普拉斯公司 | 用于治疗炎性疾病的肽化合物、缀合化合物及其用途 |
| CA3068818A1 (en) * | 2017-07-05 | 2019-01-10 | Jiangyin Mucocare Pharmaceutical Co., Ltd | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
| CN110139662B (zh) * | 2017-07-05 | 2022-03-18 | 江阴贝瑞森制药有限公司 | 肽的抗炎用途 |
-
2019
- 2019-09-14 HU HUE19856467A patent/HUE062848T2/hu unknown
- 2019-09-14 KR KR1020217010829A patent/KR102946621B1/ko active Active
- 2019-09-14 EP EP19856467.6A patent/EP3678705B1/en active Active
- 2019-09-14 BR BR112021004823-5A patent/BR112021004823A2/pt unknown
- 2019-09-14 JP JP2021514112A patent/JP7759693B2/ja active Active
- 2019-09-14 EP EP23176152.9A patent/EP4253404A3/en active Pending
- 2019-09-14 AU AU2019338582A patent/AU2019338582B2/en active Active
- 2019-09-14 PL PL19856467.6T patent/PL3678705T3/pl unknown
- 2019-09-14 ES ES19856467T patent/ES2956509T3/es active Active
- 2019-09-14 LT LTEPPCT/CN2019/105832T patent/LT3678705T/lt unknown
- 2019-09-14 HR HRP20230946TT patent/HRP20230946T1/hr unknown
- 2019-09-14 SM SM20230210T patent/SMT202300210T1/it unknown
- 2019-09-14 CN CN201980004399.1A patent/CN111601618A/zh active Pending
- 2019-09-14 MX MX2021002657A patent/MX2021002657A/es unknown
- 2019-09-14 SI SI201930561T patent/SI3678705T1/sl unknown
- 2019-09-14 US US16/645,355 patent/US11680082B2/en active Active
- 2019-09-14 MY MYPI2021001220A patent/MY205435A/en unknown
- 2019-09-14 PT PT198564676T patent/PT3678705T/pt unknown
- 2019-09-14 CN CN202310240501.6A patent/CN116785447B/zh active Active
- 2019-09-14 SG SG11202102119RA patent/SG11202102119RA/en unknown
- 2019-09-14 CA CA3112420A patent/CA3112420A1/en active Pending
- 2019-09-14 DK DK19856467.6T patent/DK3678705T5/da active
- 2019-09-14 RS RS20230654A patent/RS64436B1/sr unknown
- 2019-09-14 WO PCT/CN2019/105832 patent/WO2020052677A1/en not_active Ceased
- 2019-09-14 FI FIEP19856467.6T patent/FI3678705T3/fi active
- 2019-09-16 TW TW108133243A patent/TWI875712B/zh active
-
2021
- 2021-03-01 ZA ZA2021/01398A patent/ZA202101398B/en unknown
- 2021-03-11 IL IL281426A patent/IL281426A/en unknown
- 2021-03-11 SA SA521421448A patent/SA521421448B1/ar unknown
-
2023
- 2023-05-12 US US18/316,496 patent/US20230348536A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4253404A3 (en) | Conjugates of montelukast and peptides | |
| AU653524B2 (en) | New imidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them | |
| CO2025013480A2 (es) | Compuestos de pirido[4,3–d]pirimidina | |
| MX2022003057A (es) | Nuevos peptidos. | |
| EA201170193A1 (ru) | Новые содержащие серу липиды для применения в качестве пищевой добавки или в качестве лекарственного средства | |
| ECSP23002606A (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
| ECSP067058A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| WO2009067639A3 (en) | Variants of c-type natriuretic peptide | |
| IL275188B2 (en) | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis | |
| PE20211390A1 (es) | Compuestos antibacterianos | |
| AR062051A1 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ | |
| JP2018520999A5 (cg-RX-API-DMAC7.html) | ||
| WO2024189598A3 (en) | Acylsulfonamide kat6a inhibitors | |
| MX2020007994A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). | |
| WO2012059442A3 (en) | Neurotrypsin inhibitors | |
| MX2024006556A (es) | Inhibidores de peptido del receptor de interleucina-23. | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MX2025014276A (es) | Heterociclos biciclicos 5,6 insaturados utiles como inhibidores de la proteina receptora 3 similar a nod | |
| CN105800802A (zh) | 一种复合型无磷缓蚀阻垢剂 | |
| BR112020006576A8 (pt) | Sal ácido conjugado de n, n-dimetilglicina com ácido orgânico, composição e utilização. | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| ZA202308193B (en) | Functionalized long-chain carboxylic acids, and their use for treatment of disease | |
| ES2993255T3 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| CN105348365A (zh) | 一种胆酸衍生物及其制备方法、药物组合物和用途 | |
| CN102134269A (zh) | 糖皮质激素硝酰氧基衍生物 |